Melatonin may improve sleep, quality of life in patients with breast cancer
the ONA take:
Melatonin may be a potential therapeutic agent for improve sleep and quality of life in patients with metastatic breast cancer, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
Because fatigue and sleep problems are common among patients with cancer, researchers at the Sunnybrook Odette Cancer Centre in Toronto, Ontario, sought to investigate the effectiveness of melatonin at improving sleep.
For the phase 2 study, researchers enrolled 32 patients with metastatic breast cancer who were receiving hormonal or trastuzumab therapy. All participants took melatonin 5 mg at bedtime for 2 months.
Results showed that bedtime melatonin was associated with a significant improvement in subjective sleep, fatigue severity, sleep fragmentation and quantity, and quality of life.
The findings suggest that further research assessing the efficacy of melatonin for improving sleep and quality of life in patients with cancer is warranted.
Melatonin may be a potential therapeutic agent for improve sleep and quality of life in patients with metastatic breast cancer.
- More Than Half of Melanomas Are Self-Detected, Especially by Women
- Childhood Cancer Linked to Poor Diet Quality in Adult Survivors
- POLST Programs Can Benefit from the Relationship Between Patients and Nurse Practitioners
- Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment
- Olaratumab in Combo With Doxorubicin Approved for Soft Tissue Sarcoma
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Caregiver Mastery Linked to Patient Survival in Glioblastoma
- Treatment Facility Volume Associated With Mortality Risk in Multiple Myeloma
- Adherence to Tamoxifen, AIs Among Older Women is Low, Study Shows
- Replacing Neoadjuvant CRT with Multiagent Chemo Not Recommended for Rectal Cancer
- Study Identifies Factors Associated With Infection-related Complications in ALL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|